TF2- Small Cell Lung Cancer Radio Immunotherapy

Inclusion Criteria:

• Patients with histologic diagnosis of SCLC who are in partial response or who have failed at least two lines of standard radiation and/or chemotherapy. Outside formal contra-indication, patients must have received at least one prior platinum-based chemotherapy.

or

* Patients with histologic diagnosis of NSCLC (without activating mutation of EGFR gene) who have failed at least one line of chemotherapy (platinum in combination with a third generation drug or combination of 2 third generation drug +/-bevacizumab in case of predominance of non-squamous tumor)
* Age ≥ 18 years
* At least 4-weeks after the previous treatment and have recovered from previous radio- or chemotherapy
* Women of child-bearing potential must have a negative pregnancy test.
* Karnofsky performance status ≥ 60 or ECOG performance status 0-2Karnofsky
* Minimum life expectancy of 3 months
* Positive CEA on immunohistology or plasma CEA ≥ 10 ng/mL
* At least one measurable lesion by CT
* At least one abnormal focus by FDG-PET
* Imaging studies must be performed within 1-4 weeks before PRAIT study to document extent of disease
* Signed informed consent form.

Exclusion Criteria:

* Pregnant or lactating woman. Women of child-bearing potential will be asked to practice adequate means of birth control for a minimum of 12 months after treatment.
* Male patient refusing effective contraception for a minimum of 12 months after treatment.
* Brain metastases but patients with brain metastases controlled after treatment by Surgery or radiotherapy since more than 4 weeks are eligibles for the study. An treatment by associated corticotherapy is authorized for these patients.
* Known HIV or hepatitis
* Any serious active disease or comorbid medical condition (according to the investigator's decision and information provided in the IDB)
* Severe disorders of hemostasis or anticoagulant treatment cure
* Extensive irradiation to more than 25% of their red marrow
* Bone marrow involvement to more than 25%
* External radiation to specific organs or areas at the maximum tolerated level
* EGFR gene mutation in tumor (only for NSCLC)
* Febrile aplasia during a previous chemotherapy
* Neutrophils \< 1.5 G/l
* Platelets \< 100 G/l
* Uncontrolled diabetes
* Poor renal function (creatinine level \> 2.5 maximum normal level)
* Poor hepatic function (total bilirubin level \> 30 mmol/l, transaminases \> 2.5 maximum normal level)
* Treatment with any investigational drug within 30 days before planned PRAIT and during the study
* Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma,
* Presence of anti-antibody reactivity
* Known hypersensitivity to murine antibodies or proteins
* Adult patient unable to give informed consent because of intellectual impairment.